CCR2-Dependent Dendritic Cell Accumulation in the Central Nervous System during Early Effector Experimental Autoimmune Encephalomyelitis Is Essential for Effector T Cell Restimulation In Situ and Disease Progression

Benjamin D. Clarkson, Alec Walker, Melissa G. Harris, Aditya Rayasam, Matyas Sandor and Zsuzsanna Fabry

*J Immunol* 2015; 194:531-541; Prepublished online 10 December 2014; doi: 10.4049/jimmunol.1401320

http://www.jimmunol.org/content/194/2/531
C-C chemokine receptor 2 (CCR2) has been shown to be important in the infiltration of monocytes, DCs, and T cells into inflamed tissues (20). Despite much research, no report to date has definitively identified chemokines and chemokine receptors that may contribute to DC migration across the in vivo endothelial blood-brain barrier and into the perivascular space of the CNS postcapillary venules. Chemokine receptor CCR2 is expressed on monocytes, monocyteid DC precursors, and circulating blood DCs (19). One recent study found that human monocyte-derived DCs migrate across brain vascular endothelial cells in vitro in response to CCL2 and that DCs were distributed adjacent to CCL2 in the CNS of mice with EAE (20). CCR2 has also been previously implicated in the migration of monocytes and myeloid DCs to inflammatory sites, including infected lung (21–23), psoriasis (19, 24), diabetes mellitus (25), and rheumatoid arthritis (26, 27). In CNS tissues, it is thought that CCR2 in the CNS is implicated previously, the role of CCR2 in DC infiltration into the CNS has never been directly addressed. Our data suggest that CCR2-dependent DC recruitment to the CNS during ongoing neuroinflammation plays a crucial role in effector T cell cytokine production and disease progression, and signify that CNS-DCs and circulating DC precursors might be key therapeutic targets for suppressing ongoing neuroinflammation in CNS autoimmune diseases. The Journal of Immunology, 2015, 194: 531–541.

Dendritic cells (DCs) are APCs capable of migrating from organ tissues to regional lymph nodes and stimulating T cells to promote both tolerance and immunity to self and foreign Ag acquired in situ. In addition to their role in regulating adaptive immune responses in peripheral lymphoid organs (PLO) tissues, DCs accumulate in inflamed tissues, where they are thought to present MHC class II–restricted Ag to coinfiltrating CD4+ T cells (1–3). We and others have shown that DCs accumulate in perivascular spaces and within inflammatory foci in mouse models of stroke, multiple sclerosis, epilepsy, and traumatic brain injury, or after intracerebral injection of Ag or cytokines (4–14). In the context of experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis, CD11b+CD11c+ myeloid DCs, which are derived from blood monocytes, represent the majority of these accumulating DCs (11, 13, 15). Recruitment of immature DCs to the CNS during EAE has also been shown to be dependent upon α4β1 integrin, which binds to VCAM-1 on brain endothelium (16). Ex vivo assays suggest these DCs may be important for cross-presentation of MHC class I–restricted Ag to CD8+ T cells and restimulation of CD4+ T cells with MHC class II–restricted myelin Ag (11, 17, 18). Yet, how these inflammatory DCs home to the CNS remains unclear, and whether these cells are essential tissue APCs for in situ reactivation of CNS-infiltrating T cells is unknown.

Despite much research, no report to date has definitively identified chemokines and chemokine receptors that may contribute to DC migration across the in vivo endothelial blood-brain barrier and into the perivascular space of the CNS postcapillary venules. Chemokine receptor CCR2 is expressed on monocytes, monocyteid DC precursors, and circulating blood DCs (19). One recent study found that human monocyte-derived DCs migrate across brain vascular endothelial cells in vitro in response to CCL2 and that DCs were distributed adjacent to CCL2 in the CNS of mice with EAE (20). CCR2 has also been previously implicated in the migration of monocytes and myeloid DCs to inflammatory sites, including infected lung (21–23), psoriasis (19, 24), diabetes mellitus (25), and rheumatoid arthritis (26, 27). In CNS tissues, it was shown that astrocyte-specific overexpression of the CCR2 ligand CCL2 leads to spontaneous asymptomatic accumulation of...
perivascular monocytes in the brain with little infiltration into the CNS parenchyma (28). In relapsing-remitting EAE in Lewis rats, CCL2 expression correlates with disease relapse (29). Similarly, CCL2+/− mice have impaired monocyte recruitment to CNS perivascular spaces during CNS viral infection (30). Consistent with this, CCR2−/− mice are protected from EAE, and bone marrow (BM) chimera experiments revealed that host CCL2 deficiency, but not donor deficiency, protected mice from EAE by reducing the recruitment of monocytes and myeloid DCs (31), suggesting the CCL2–CCR2 axis may be important for myeloid cell recruitment to the perivascular spaces of the inflamed CNS. Additionally, whereas adoptively transferred CCR2−/− T cells are capable of inducing EAE in wild-type (WT) mice, WT T cells are incapable of inducing EAE in CCR2−/− mice. This implies that CCR2 is required on one or more immune cell subsets other than T cells for disease onset (22, 32, 33). However, the potential role of CCR2 in recruiting myeloid DCs to the CNS remains unknown and has been largely overshadowed by the marked amelioration of EAE progression associated with reduced monocyte recruitment to CNS in CCR2−/− mice.

Thus, we sought to determine whether CCR2 is directly required for DC recruitment into CNS perivascular space during the onset of neuroinflammation, and whether specific attenuation of DC recruitment to CNS tissues could slow disease progression. We report that both CNS-infiltrating DCs and BM-derived DCs (BMDCs) express CCR2 and migrate across brain endothelium in response to CCL2 in vitro and in vivo, and that CCR2−/− DCs or DC precursors are deficient in their accumulation in the inflamed CNS despite abundance in blood and PLO tissues. Moreover, ablation of CCR2+/+ DCs or MHc class II+ DCs during EAE clinical onset (but not at later time points) delays disease progression. These data suggest that CCR2-dependent DC recruitment to the CNS is essential for restimulation of CD4+ T cells with MHc class II–restricted myelin Ag during onset of EAE, but is dispensable at later time points.

Materials and Methods

Mice and BM chimeras

C57BL/6 WT (stock 000664), B6.129S4-Ccr2tm1Ifc/J (CCR2−/−, stock 004999), B6.PL-Thy1a/CyJ (Thy1.1, stock 000406), B6.FVB-Tg(lgα-diphtheria toxin [DT] receptor [DTR]/EGFP)57Lan/J (CD11c-DTR, stock 004509), and B6.Cg-Tg(CAG-DsRed*MST)1Nagy/J (Dsred, stock 006051) mice were obtained from The Jackson Laboratory (Bar Harbor, ME). C57BL/6-Tg(lgα-Venus)1Mnz/J (CD11c-eYFP) transgenic mice on the C57BL/6 background were a generous gift of M. C. Nussenzweig (Rockefeller University, New York, NY). C57BL/6-Tg(Tcra2D2, Tcrb2D2)1Kuch/J (2D2) TCR-transgenic mice with myelin oligodendrocyte glycoprotein (MOG)35–55 transgenic mice on the C57BL/6 background were a generous gift of M. C. Nussenzweig (Rockefeller University, New York, NY). C57BL/6-Tg(Tcra2D2, Tcrb2D2)1Kuch/J (2D2) TCR-transgenic mice with myelin oligodendrocyte glycoprotein peptide (MOG)35–55−/− restricted CD4+ T cells were a gift of V. Kuchroo (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA). The 2D2 mice were crossed with homozygous Thy1.1+ or Dsred+ mice to generate 2D2Thy1+ or 2D2Dsred+ mice. Single cell suspensions for adoptive cell transfer experiments were used. Mice were genotyped by PCR from genomic DNA extracted from tail or ear clippings. All F1 offspring used in this study were conducted in strict compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the University of Wisconsin Center for Health Sciences Research Animal Care Committee.

Induction of EAE

EAE was induced as previously described (34). Briefly, emulsion of equal volumes of CFA and 100 μg MOG35-55 (MEVGYRSPFSRVHLYRNGK) supplemented with Mycobacterium tuberculosis H37Ra (5 mg/ml; Difco, Detroit, MI) was injected s.c. in the scapular region of each mouse. MOG-CFA mixture was emulsified by sonication using an ultrasonic homogenizer (Model 300VTT equipped with a titanium cup tip; Biologies, Manassas, VA). Pertussis toxin (200 ng/mouse, i.p.) was injected on days 0 and 2 relative to immunization. Clinical scores were monitored daily in a blinded manner and recorded as follows: 0, no clinical disease; 1, flaccid tail; 2, gait disturbance or hind limb weakness; 3, hind limb paralysis and no weight bearing on hind limbs; 4, hind limb paralysis with forelimb paresis and reduced ability to move around the cage; and 5, moribund or dead. The mean daily clinical score and SEM were calculated for each group. The significance of differences was calculated by Student’s t and Wilcoxon tests, as described elsewhere (35).

Histology

For fluorescent microscopy, CNS tissues were fixed overnight in 3% formalin/25% sucrose, embedded in OCT compound (Tissue-Tek Sakura, Torrance, CA), and stored at −80 °C. Cryosections (5–10 μm) were cut from OCT-embedded tissue samples, postfixed for 20 min in ice-cold acetone, and washed with PBS (25–50 min). Sections were mounted with ProLong Gold antifade reagent (Invitrogen, Carlsbad, CA) with DAPI. Fluorescent images were acquired at original magnification ×40–400 with Picture Frame software (Optronics) using an Olympus BX41 microscope (Leeds Precision Instruments) equipped with a camera (Optronics, Goleta, CA). For bright field microscopy, CNS tissues were postfixed in 10% formalin and embedded in paraffin for sectioning. Tissue sections were stained with H&E or luxol fast blue to detect infiltrating cells or demyelination, respectively. Bright-field images were acquired at ×40–400 final original magnification with Q-Capture software using an Olympus BX40 microscope equipped with a Q-Color 3 camera (Olympus America). Digital images were processed and analyzed using Photoshop CS4 software (Adobe Systems). Color balance, brightening, and contrast settings were manipulated to generate final images. All images were applied equally to entire image.

Mononuclear cell isolation

For immune cell isolation from CNS tissues, brains and spinal cords were removed from saline-perfused mice, weighed, minced, and incubated with collagenase type IV (1 mg/ml) and DNase (28 U/ml) at 37 °C for 45 min. Samples were further homogenized by trituration and filtered through 70-μm cell strainers. The cell suspension was washed with HBSS supplemented in 70% Percoll (Pharmacia, Piscataway, NY), and overlaid with 30% Percoll. The gradient was centrifuged at 2500 rpm (625 × g) for 30 min at 4 °C without break. Mononuclear cells were collected from the gradient interface and washed once for further analysis. For immune cell isolation from PLO tissues, spleen and cervical lymph nodes were gently dissociated between frosted slides and passed through 70-μm cell strainers. Blood cells were collected by cardiac puncture and washed. Bone marrow cells were collected aseptically from the popliteal lymph nodes (PLO) and transferred into 100 vol 10 mM EDTA HBSS. RBCs were removed from spleen and blood samples using ammonium chloride potassium carbonate RBC lysis buffer and repeated washing.

Intracellular cytokine staining and flow cytometry

For ex vivo recall responses, single-cell suspensions from various tissues were cultured at 37 °C in 10% PBS in RPMI 1640 media containing GolgiStop (BD Biosciences, San Jose, CA) with or without additional stimulating agents, including PMA (50 ng/ml) and ionomycin (1 μg/ml), MOG35-55 peptide (2–20 μg/ml), or anti-CD3 (1 μg/ml)/anti-CD28 (2 μg/ml) for 5 h. For immune-fluorescent labeling, 106 cells isolated from CNS and PLO tissues were incubated for 30 min on ice with saturating concentrations of fluorochrome-labeled mAbs. Unlabeled 2.4G2 mAb (40 μg/ml) was used to block nonspecific binding of fluorochrome-labeled mAbs to Fc receptors. After staining, cells were washed three times using HBSS ultralow buffer (1% BSA in PBS). For intracellular staining, cell suspensions were then fixed and permeabilized overnight (4°C) with Cytofix/Cytoperm solution (BD Biosciences). The next day, cells were washed with Perm/Wash buffer (BD Biosciences) and stained with mAbs against IFN-γ and IL-17. Fluorochrome-labeled mAbs were acquired at CD45 (30-F11), CD11b (M1/70), CD11c (HL3), CD80 (16-10A1), CD86 (GL1), CD40 (3/23), PDL1 (MR1), PDL2 (T253), LA+ (AF6-1201), B220 (RA-B2D), CD4 (RM4.5), Vβ11 (R3-15), Vβ11.1 (OX7), CD8a (53–67), IFN-γ (XMG1.2), IL-17 (TC11-18H10), and appropriate isotype controls were purchased from BD Biosciences (Minneapolis, MN). Anti-CCR2 Ab
The Journal of Immunology 533

Hands, DT treatment was not associated with noticeable weight loss. Loss was observed following DT treatment, animals were weighed and scored and body condition scoring starting at day 7. If noticeable weight was used to compare measures made between two groups. The values *p* < 0.05 were considered significant.

**Results**

**Ablation of CD11c+ DCs during preclinical EAE ameliorates disease**

In the context of EAE, DCs are thought to be important for T cell priming and the initiation of adaptive immunity to myelin Ags in PLO tissues. However, T cells also require TCR restimulation before use. Prior to disease onset highlighted the essential role of DCs—potentially as proinflammatory APCs during this time period when these cells first begin to accumulate in the CNS (15, 40) (our unpublished observations).

**CD11c+ BMDCs and CNS-infiltrating DCs express CCR2, and CCR2 contributes to BMDC infiltration into the inflamed CNS**

CD11c+ BMDCs have been implicated in monocyte migration from blood and BM into tissues. Thus, we sought to determine the role of CCR2 in DC recruitment to the CNS during neuroinflammation. We observed a dose-dependent increase in migration of BMDCs across mouse brain endothelial cell monolayers in response to CCL2, as previously reported (20) (Fig. 2A). Similarly, we found that relative to mice intracerebrally injected with PBS, mice that received intracerebral injections of CCL2 exhibited an increased frequency of brain-infiltrating myeloid cells (CD45-high CD11b+) and DCs (CD45-high CD11b+CD11c+), but not microglia (CD45-low CD11b) (Fig. 2B). Flow cytometry of cells isolated from CNS and peripheral lymphoid organ tissues during EAE also confirmed the expression of the CCR2 on CD11b+CD11c+ brain infiltrates and splenocytes (Fig. 2C). As in vitro differentiated BMDCs express high level of CCR2 (Fig. 2D, left column), we decided to further test the direct role of CCR2 in DC recruitment to the inflamed CNS. We cultured BMDCs from CCR2-deficient (CCR2−/−) mice and congenic CCR2-deficient (CCR2−/−)CD11c-eYFP mice and transferred equal numbers of these cells (25 × 10^6/mouse) into congenic WT colorless recipients with active clinical disease at day post-immunization (DPI) 12–13. Cells from CNS and PLO tissues were isolated 4 d later to compare BMDC recruitment. As shown, CCR2−/− and CCR2−/−/BMDCs expressed similar levels of the eYFP transgene on the day of transfer (Fig. 2D, left column). We observed no difference in the expression of CD11b or costimulatory markers between CCR2−/− and CCR2−/−/BMDCs (data not shown). At peak disease (DPI 16–17), the frequency of CD11c-eYFP BMDCs in spleens (Fig. 2D) and cervical lymph nodes (cLN; data not shown) did not differ between mice receiving CCR2−/− and CCR2−/−/BMDCs. In contrast, at this time point, higher numbers of CCR2−/− CD11c-eYFP BMDCs were present in inflamed CNS tissues compared with their CCR2−/− counterparts (Fig. 2D). Interestingly, mice receiving CCR2−/− BMDCs during early disease exhibited larger increases in clinical scores when assessed 2–4 d later (Fig. 2D, 2E), suggesting that—much as ablating DCs during this time period can delay EAE clinical progression—increasing the frequency of circulating CD11c+ DCs during this time frame can accelerate disease progression. To control for the potentially confounding influence of endpoint clinical score on BMDC recruitment, we also compared recruitment of CCR2−/− and CCR2−/−/BMDCs to CNS tissues, grouping mice with similar clinical scores. Even within these constraints, we saw a higher frequency of CCR2−/− BMDCs in CNS tissues compared with CCR2−/−/BMDCs (Fig. 2E). These
data provide direct evidence that CCR2 expressed on DCs promotes recruitment of these cells to the inflamed CNS.

**Compared with CCR2<sup>+/+</sup> cells, adoptively transferred CCR2<sup>−/−</sup> DC precursors do not accumulate in the CNS during EAE, despite abundance in blood**

To further understand the role of CCR2 in regulating CD11c<sup>+</sup> cell migration into the CNS in vivo, we induced EAE in CCR2<sup>+/+</sup> mice expressing Dsred fluorescent protein ubiquitously under the CAG promoter (CD45.2<sup>+/+CCR2<sup>+/+Dsred</sup>), as well as in CCR2<sup>−/−</sup> colorless mice (CD45.2<sup>+CCR2<sup>−/−Dsred</sup>−/−) and CD45.1<sup>+/+</sup> colorless mice. At DPI 12 or 16, we transferred 50/50 mixtures of BM cells from CD45.2<sup>+/+CCR2<sup>−/−Dsred</sup>−/− and CD45.2<sup>+/+CCR2<sup>+/+Dsred</sup>−/+ donor mice into congenic CD45.1<sup>−/+</sup> recipients with synchronous EAE (10–15 × 10<sup>6</sup>/mouse, i.v.). Four days later, we isolated immune cells from CNS and PLO tissues and analyzed the frequency of CCR2<sup>+/+</sup> (Dsred<sup>+</sup>) and CCR2<sup>−/−</sup> (Dsred<sup>−</sup>) cells among CD45.2<sup>+</sup>CD11b<sup>+</sup>CD11c<sup>+</sup> donor-derived DCs by flow cytometry. We first gated on CD45.2<sup>+</sup>CD45.1<sup>−/+</sup> cells (Fig. 3A) and then gated on CD11b<sup>+</sup>CD11c<sup>+</sup> cells to compare the relative frequency of CCR2<sup>+/+</sup> (Dsred<sup>+</sup>) and CCR2<sup>−/−</sup> (Dsred<sup>−</sup>) donor-derived DCs in BM, blood, spleen, and CNS (gating shown in Fig. 3D). At both end points (DPI 16 and DPI 20), we observed similar frequencies of CCR2<sup>+/+</sup> and CCR2<sup>−/−</sup> DCs in spleen, with elevated relative frequencies of CCR2<sup>−/−</sup> DCs in both BM and blood (Fig. 3C). Despite the relatively high level of CCR2<sup>−/−</sup> DCs observed in circulation, we detected a much lower frequency of CCR2<sup>−/−</sup> DCs in CNS tissues relative to CCR2<sup>+/+</sup> DCs, especially at the earlier time point (DPI 12–16). To illustrate this point, we also present the relative frequency of CCR2<sup>+/+</sup> and CCR2<sup>−/−</sup> DCs in blood and CNS of individual recipient mice (Fig. 3B). In all cases, CCR2<sup>−/−</sup> DCs were present at lower frequencies in CNS tissues relative to their frequency among donor cells in the blood of the same mouse. The reciprocal was true of CCR2<sup>+/+</sup> DCs, which were present at higher frequencies in CNS tissues than in blood of all animals (mean difference 61.8% ± 10.9%, DPI 12–16; 37% ± 12.3%, DPI 16–20). These studies provide strong evidence that CCR2 is crucial for DC recruitment to the inflamed CNS, at least within the limited time frames under which we could study this phenomenon in vivo.

**CCR2<sup>−/−</sup> DCs show less accumulation in the inflamed CNS in mixed BM chimera when compared with CCR2<sup>+/+</sup> DCs**

Next, we generated mixed BM chimera mice, wherein we could track CCR2-dependent DC recruitment to the CNS throughout the course of EAE onset. We reconstituted WT (C57BL/6) mice with a 50/50 mixture of WT BM cells and BM cells from either congenic CCR2<sup>−/−</sup>CD11c-eYFP or CCR2<sup>+/+</sup>CD11c-eYFP mice. After reconstitution and recovery, we immunized these mice with MOG<sub>35-55</sub> CFA to induce EAE. We isolated immune cells from CNS and PLO tissues from these mice 8, 12, and 16 d later to compare recruitment of CCR2<sup>+/+</sup> and CCR2<sup>−/−</sup> CD45<sup>+</sup>CD11c-eYFP cells (gating shown in Fig. 4A). As expected, due to the presence of a partially WT hematopoietic system, no difference in the onset or severity of EAE was observed between mice in these groups (data not shown). We also observed similar levels of CD11c-eYFP<sup>+</sup> cells in both spleen and cLNs of CCR2<sup>+/+</sup>CD11c-eYFP and CCR2<sup>−/−</sup>CD11c-eYFP mice. After reconstitution, we observed similar levels of donor-derived CD11c-eYFP<sup>+</sup> cells in both spleen and cLNs of CCR2<sup>+/+</sup>CD11c-eYFP and CCR2<sup>−/−</sup>CD11c-eYFP BM recipients (Fig. 4C). In sharp contrast, as early as DPI 12, we saw markedly reduced accumulation of CCR2<sup>−/−</sup>CD11c-eYFP<sup>+</sup> cells in CNS relative to CCR2<sup>+/+</sup>CD11c-eYFP<sup>+</sup> cells. To assess regional differences in DC recruitment, we dissected CNS anatomical regions prior to immune cell isolation and flow cytometric analysis. By this method, we found that, whereas the frequency of host-derived radioresistant microglial cells (CD45-low CD11b<sup>+</sup>) did not differ between groups in most regions, the frequency of donor-derived CD11c-eYFP<sup>+</sup> cells was markedly lower in CCR2<sup>−/−</sup>CD11c-eYFP<sup>+</sup> cells in all CNS tissues analyzed, save hippocampus. These differences in recruitment persisted or increased in all CNS anatomical regions by DPI 16 (Fig. 4B).

Further investigation of the in situ distribution of these CD11c-eYFP<sup>+</sup> cells by fluorescent microscopy revealed that the majority of CD11c-eYFP<sup>+</sup> cells found in the CNS of CCR2<sup>−/−</sup>/CD11c-eYFP<sup>+</sup> recipients were restricted to the choroid plexus of the lateral and third ventricles adjacent to the hippocampus. A minority of CD11c-eYFP<sup>+</sup> cells in these mice were also found in the taenia tecta and the islands of Calleja on the ventral side of the olfactory...
tubercle (Fig. 4D). In contrast, CCR2<sup>+/+</sup>CD11c-eYFP recipients exhibited disseminated infiltration of CD11c-eYFP<sup>+</sup> cells throughout the CNS, with prominent infiltrates in the white matter tracks of the cerebellum, the cerebral cortex, and ventral portions of the olfactory bulb, as well as the ventricles and surrounding neuropil of the hippocampus and superior colliculus (Fig. 4D). These studies confirmed that CCR2 is required for DC recruitment to the CNS, but not PLO tissues during EAE.

Ablation of CCR2<sup>+/+</sup> DCs during EAE clinical onset delays progression

To explore the functional consequences of DC recruitment to CNS tissues on disease progression, we generated mixed BM chimera mice in which we could transiently ablate CCR2<sup>+/+</sup> DCs and thereby diminish DC recruitment to the CNS. We generated mixed BM chimeric mice by reconstituting irradiated WT mice with BM cells from congenic CD11c-DTR mice and BM cells from CCR2<sup>−/−</sup> or CCR2<sup>+/+</sup> mice. These mice are referred to hereafter as CCR2<sup>−/−</sup>:CD11cDTR mice and CCR2<sup>+/+</sup>:CD11cDTR mice. After reconstitution and recovery, we immunized these mice with MOG/CFA to induce EAE and administered DT (625 ng/kg, i.p.) during disease onset (DPI 8–12) or during peak disease (DPI 14–18) to ablate CD11c-DTR<sup>+</sup> DCs. When we administered DT during peak disease, we observed no difference between CCR2<sup>+/+</sup>:CD11c-DTR and CCR2<sup>−/−</sup>:CD11c-DTR mice in subsequent clinical scores or effector T cell cytokine production within the CNS (data not shown). In contrast, when we ablated CD11c-DTR<sup>+</sup> DCs during clinical onset, DT-treated CCR2<sup>−/−</sup>:CD11c-DTR mice exhibited a significant delay in clinical progression compared with either DT-treated CCR2<sup>+/+</sup>:CD11c-DTR BM recipients or PBS-treated CCR2<sup>−/−</sup>:CD11c-DTR recipients (Fig. 5A). Ablation of CD11c-DTR<sup>+</sup> DCs also correlated with reduced levels of IFN-γ- and IL-17–producing CD4<sup>+</sup> T cells as well as reduced levels of IFN-γ–producing CD8<sup>+</sup> T cells in the brain and spinal cord of these mice relative to controls (Fig. 5B). Further examination of spinal cord tissues revealed a reduced number of inflammatory foci and demyelinated lesions in mice with ablated CCR2<sup>+/+</sup> DCs (micrographs shown in Fig. 5D; demyelination quantified in Fig. 5C). These data indicate that CCR2-dependent recruitment of CD11c<sup>+</sup> DCs to CNS tissues during onset of EAE critically contributes to CNS-infiltrating T cell cytokine production and EAE disease pathology.

Preclinical ablation of MHC class II<sup>+</sup> DCs prevents recruitment of Ag-experienced encephalitogenic T cells to CNS and ameliorates EAE

Once they have infiltrated the CNS, CD4<sup>+</sup> T cells must first reencounter their cognate Ag in the context of MHC class II molecules on local APCs to carry out effector functions, such as cytokine secretion (36, 37, 41). Thus, to explore the potential role of DCs as tissue APCs that might contribute to T cell restimulation in situ, we analyzed the relative localization of CNS-infiltrating DCs and T cells. We purified MOG-specific CD4<sup>+</sup> T cells from TCR transgenic 2D2 mice bred onto a Dsred background (2D2.Dsred)
and transferred these cells into CD11c-eYFP mice prior to EAE induction by MOG immunization to visualize the in situ localization of CNS-infiltrating encephalitogenic MOG-specific 2D2 Dsred and coinfiltrating CD11c-eYFP+ DCs by fluorescent microscopy. As shown in Fig. 6A, both MOG-specific CD4+ T cells and CD11c-eYFP+ cells accumulated within the ventricles and surrounding tissues of the CNS at the time of clinical onset (DPI 12). We observed extensive colocalization of these cells within the CNS (our unpublished data), suggesting these cells may form functional interactions in situ.

To determine whether these colocalizations could represent functional T cell–APC (TCR–Ag–MHC class II) interactions, we analyzed CNS leukocyte subsets for the expression of MHC class II by flow cytometry. Whereas CD11c+ cells represented a minority of total leukocytes within inflamed CNS tissues, CD11c+ cells exhibited higher frequencies of MHC class II+ cells than CD11c– cells among both CD11b+ and CD11b– cell subsets (Fig. 6B)—indicating that CNS-infiltrating CD11c+ cells are well equipped to regulate the activity of coinfiltrating CD4+ T cells through MHC class II–Ag–TCR interactions. This is consistent with a recent study showing higher expression of MHC class II on CD11c+ than CD11c– cells (42). Thus, to explore this potential, we generated mixed BM chimera mice in which we could transiently ablate MHC class II+ DCs do not accumulate in inflamed CNS despite abundance in blood. CD45.2+ BM cells were adoptively transferred into CD45.1+ hosts at day 12 or 16 of EAE, and mice were euthanized for tissue collection 4 d later at day 16 or 20, respectively. (A) Flow plots showing spleen cells from CD45.1 mice adoptively transferred with either PBS or equal mixtures of BM from CD45.2+/+CCR2+/+ DsRed+ and CD45.2+/+CCR2+/+ DsRed+ mice. (B) Frequency of CCR2+/+(Dsred+)) and CCR2–/–(Dsred–) among donor (CD45.2+) cells in blood and CNS. Lines indicate difference in frequency in blood and CNS from individual mice. (C) Frequency of CCR2+/+(Dsred+)) and CCR2–/–(Dsred–) among donor (CD45.2+) cells in BM, spleen, blood, and CNS at days 16 and 20 of EAE. Data are representative of three independent experiments with n = 3 mice per group. Error bars indicate SEM. (D) Representative flow plots showing percentage of cells CCR2+/+(Dsred+)) and CCR2–/–(Dsred–) among donor (CD45.2+/+CD45.1–) CD11b+ and CD11c+ cells in blood, spleen, and CNS of mice from (A). Data are representative of three independent experiments with n = 3 mice per group.

of IFN-γ–producing and IL-17–producing CD4+ MOG-specific T cells in the CNS at peak disease (DPI 16, Fig. 6D)—indicating that MHC class II–dependent Ag presentation by CD11c+ DCs is required after initial T cell priming for disease onset.

In separate experiments using these mice, we transferred (1–5 × 10^6, i.v.) sorted populations of MOG-specific CD4+ Ag-experienced 2D2 T cells (CD44+CD62L+CD4+ Vβ11+ Dsred+ Thy1.1+, isolated from MOG35–55–immunized mice) and naive 2D2 T cells (CD44+CD62L+CD4+ Vβ11+ Dsred+ Thy1.1+, isolated from unimmunized mice), which had been fluorescently labeled with Violet Cell Trace to track proliferation. T cell populations were transferred into MHC class II+/+CD11c-DTR and MHC class II+/−CD11c-DTR mixed BM chimera mice 1 d following the first administration of DT (DPI 9) to ensure DC ablation. At peak disease (DPI 16), immune cells were isolated from CNS and PLO tissues, and accumulation and proliferation of transferred naive (CD4+ Vβ11+ Thy1.1+ Dsred+ and Ag-experienced (CD4+ Vβ11+ Thy1.1+ Dsred+) 2D2 T cells were analyzed by flow cytometry (gating shown in Fig. 6F). As shown, transferred naive T cells displayed minimal proliferation in CNS or PLO tissues, and no difference in frequency of proliferated cells was observed between DT-treated and PBS-treated mice. However, we did observe a reduction in the frequency of total unpolarized cells in both spleens and cLNs of mice in which MHC class II+ Dcs had been ablated by DT treatment, indicating—not surprisingly—that MHC class II+ DCs are required for survival of circulating naive donor T cells. More importantly, whereas the frequency of proliferated Ag-experienced 2D2 T cells was not statistically different in either cLNs or spleens of PBS- or DT-treated mice, ablation of MHC class II+/− DCs profoundly diminished the CNS recruitment of transferred MOG-specific Ag-experienced CD4+ T cells (p = 0.0096, Fig. 6E). In summary, these data together with our previous findings support the conclusion that CCR2-dependent recruitment of CD11c+ DCs to
the CNS during onset of EAE contributes to disease progression by supporting the CNS recruitment of Ag-experienced encephalitogenic T cells and production of inflammatory cytokines by these cells through MHC class II–dependent in situ restimulation.

Discussion

Building on previous work demonstrating the importance of CCR2/CCL2 axis in neuroinflammation (20, 22, 29, 31–33, 43, 44), to our knowledge, we show for the first time that CCR2 is essential for DC recruitment to the CNS during EAE. Specifically, we show that, unlike for monocytes, CCR2 might not be essential for emigration of DC from BM, as CCR2<sup>−/−</sup> DCs were found in blood and spleen in mixed BM chimera mice. However, despite their...
abundance in blood and peripheral lymphoid organ tissues, CCR2−/− DCs failed to accumulate in the inflamed CNS, suggesting that CCR2 directly contributes to DC migration from blood to CNS tissues. We also show that CCR2-dependent DC migration into the inflamed CNS is essential for disease progression during the early effector phase of EAE and that CNS-
infiltrating DCs contribute to this progression by presenting Ag to encephalitogenic CD4+ T cells in the context of MHC class II.

Several studies have shown that DCs contribute to demyelinating lesion formation by promoting T cell activation and infiltration of the parenchyma through multiple mechanisms, including breakdown of the glia limitans (45, 46), chemokine secretion (47–49), and MHC- and cofactor-dependent restimulation (2, 3, 11, 18, 36, 37, 39, 50–52). To enter CNS parenchyma, perivascular cells must cross the glia-limitans and its associated basement membrane. Matrix metalloproteinases (MMPs), especially MMP-9 and MMP-2, which are required for EAE clinical onset, have been shown to contribute to breakdown of dyster-glycan linkages between astroglial end feet and the glia limitans basal lamina (45). These MMPs are thought to be produced by perivascular myeloid cells. We have shown that, upon transmigrating across brain microvessel endothelial cells in vitro, DCs upregulate expression of MMP9 and MMP2 (46), suggesting that this might be one mechanism by which DCs promoted infiltration into the CNS parenchyma during EAE. Others demonstrated that human monocytes transform into DCs upon in vitro migration across artificial blood brain barriers and upregulate expression of the cytokines TGF-β and IL-6, which might promote differentiation of infiltrating effector T cells into inflammatory Th17 cells (50). Tissue DCs also produce T cell–attracting chemokines (53), and in murine glioma models have been shown to attract cytotoxic T cells to the tumor microenvironment through CXCL10 (47). Additionally, DCs producing CXCL13 have been detected in ectopic lymphoid structures in the cerebral meninges of patients with secondary progressive multiple sclerosis (MS) (48) and in mice with EAE (49), which may attract T cells or promote DC–T cell clustering and contact-dependent interactions in the perivascular space.

Despite the extensive knowledge describing the important role of DCs in initiating CNS neuroinflammation, the exact mechanism regarding their migration into the CNS is less known. In this work, we demonstrate that CCR2-mediated migration is critical for DC accumulation in the CNS and provide further evidence that CNS DCs promote EAE disease progression through MHC class II–dependent restimulation of effector T cells. CNS-infiltrating T cells must re-encounter their cognate Ag in the context of MHC molecules to carry out effector functions, such as cytokine secretion. In seminal experiments, Greter et al. (3) have shown that restricting Ag presentation by MHC class II to BM-derived CD11c+ cells is sufficient for EAE onset and progression. In this study, we propose that infiltrating CD11c+ cells are not only sufficient but also required for T cell restimulation during EAE disease onset. Consistent with our data, ex vivo assays have shown that CNS myeloid DCs—although not macrophages or microglia—present endogenously acquired myelin Ags to T cells and drive effector T cell differentiation (1, 11). More recently, Wlodarczyk et al. (42) have shown that, during EAE, CD11c+ cells found in the CNS include both infiltrating CD11c+ cells and CD11c− microglia. They further showed that, unlike CD11c− microglia, CD11c+ microglia expressed MHC class II and were capable of stimulating proliferation of myelin-specific T cells. However, compared with infiltrating CD11c+ cells, these cells were deficient in their expression of third-signal cytokines necessary for driving Th1 and Th17 cell differentiation, including IL-1β, IL-12, IL-6, and IL-23, and favored Th2 and T regulatory differentiation instead. Interestingly, they also showed that infiltrating CD11c+ cells expressed higher levels of CCR2 than CD11c− or CD11c− microglia. Additionally, recent work has shown that DC–T cell interactions in the CNS are important for cross presentation of CNS Ags to CD8+ T cells (18) and epitope spreading among CD4+ T cells (2), both of which are thought to contribute to MS disease progression. In humans, MHC class II+ DCs are present in demyelinating MS lesions, where they have been shown to acquire myelin debris and interact with proliferating T cells (52). Taken together, these studies strongly imply a central role for CNS DCs in driving T cell restimulation in situ. This hypothesis is further supported by studies using the adoptive transfer EAE model, in which i.v. delivery of myelin Ag during initial T cell entry into the CNS promoted local T cell activation and exacerbated disease (54). The CNS-specific effect of this study was confirmed by intravital imaging of myelin-specific T cells in meningeal tissue, in which Pesic et al. (39) noted increased T cell infiltration into parenchyma following intrathecal injection of Ag-pulsed DCs.

Similarly, we previously demonstrated that, during EAE, intracerebral injection of myelin Ag-pulsed DCs exacerbates disease and promotes MOG-specific T cell recruitment, cytokine production, and proliferation (34). In line with these data, our present studies show that depleting DCs during EAE disease onset delays disease progression. In contrast, others have previously shown that CD11c+ cells may be dispensable during the priming phase of EAE (day 0–10) (55). We show similarly that depletion of CD11c+ cells after disease onset does not support recovery—suggesting an important window period during the early effector phase of EAE in which DCs are required for onset of neuroinflammation. Outside this window, it is likely that CD11c+ cells function are non-rate limiting and/or redundant with other APCs such as B cells, macrophages, or other CD11c+ DC populations. Moreover, these findings could imply that DCs play different, potentially redundant and nonredundant roles during distinct phases of EAE pathogenesis. Indeed, in our hands, depletion of DCs at later time points tended to worsen EAE or slow recovery, perhaps due to the presence of a tolerogenic DC population during the recovery phase. This is consistent with previous reports in which DCs isolated from CNS during EAE onset stimulated robust Th1 and Th17 responses, whereas DCs isolated at later time points were inefficient APCs that supported regulatory T cell–mediated suppression (1, 56, 57).

A nonredundant pathogenetic role of CD11c+ DCs during EAE onset is consistent with previous work in which reducing the number of circulating DCs indirectly by neutralizing the DC growth factor FLT3L ameliorated EAE (58). Conversely, Greter et al. (3) showed that EAE clinical disease is exacerbated when the level of circulating DCs is increased by i.v. administration of FLT3L-Ig, and others have shown that FLT3L administration causes spontaneous EAE in transgenic mice constitutively expressing CCL2 in CNS tissues. We show similarly that directly increasing the level of circulating DCs during active disease by i.v. transfer of high numbers of CCR2+/− BMDCs accelerates disease progression. We also show that transient ablation of CCR2+/− or MHC class II+/− DCs ameliorates disease—suggesting that the observed DC contribution to EAE disease progression at this time point is dependent upon both CCR2-mediated recruitment to effector tissues and MHC class II–mediated restimulation of Ag-experienced T cells within the CNS.

In summary, our findings suggest that targeted strategies that inhibit the CCR2-dependent migratory capacity or MHC class II–dependent Ag-presentation capacity of circulating DCs may be beneficial during acute neuroinflammatory episodes or relapses in CNS autoimmune disease. Because CCR2 contributes to an array of cell migration events in vivo, selective targeting of circulating DCs would be crucial to minimizing potential side effects of CCR2 inhibitors. Future work should focus on exploring the therapeutic potential of CCR2 inhibition using selective delivery systems that target DCs, as well as identifying molecules that specifically contribute to DC migration across the blood brain barrier.
Acknowledgments

We thank Satoshi Kinoshita for expert histopathology services and members of our laboratory for helpful discussions and constructive criticisms of this work. We also thank Khen Macvily for expertise provided for cytfluorimetry.

Disclosures

The authors have no financial conflicts of interest.

References


